Adrenocortical carcinoma: Diagnosis, prognostic classification and treatment of localized and advanced disease

Fassnacht, 2016, Management of adrenal incidentalomas: European Society of Endocrinology Clinical Practice Guideline in collaboration with the European Network for the Study of Adrenal Tumors, Eur. J. Endocrinol., 175, G1, 10.1530/EJE-16-0467 Fassnacht, 2018, European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors, Eur. J. Endocrinol., 179, G1, 10.1530/EJE-18-0608 Fassnacht, 2020, ESMO Guidelines Committee. Electronic address: [email protected], Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann. Oncol. Off. J. Eur. Soc. Med. Oncol., 31, 1476, 10.1016/j.annonc.2020.08.2099 Kiseljak-Vassiliades, 2020, American Association of Clinical Endocrinology Disease state clinical review on the evaluation and management of adrenocortical carcinoma in an adult: a practical approach, Endocr. Pract. Off. J. Am. Coll. Endocrinol. Am. Assoc. Clin. Endocrinol., 26, 1366 Crona, 2019, Adrenocortical carcinoma - towards genomics guided clinical care, Nat. Rev. Endocrinol., 15, 548, 10.1038/s41574-019-0221-7 Arlt, 2011, Urine steroid metabolomics as a biomarker tool for detecting malignancy in adrenal tumors, J. Clin. Endocrinol. Metab., 96, 3775, 10.1210/jc.2011-1565 Thomas, 2018, Interobserver agreement in distinguishing large adrenal adenomas and adrenocortical carcinomas on computed tomography, Abdom. Radiol. N. Y., 43, 3101, 10.1007/s00261-018-1603-3 Ahmed, 2020, Radiomic mapping model for prediction of Ki-67 expression in adrenocortical carcinoma, Clin. Radiol., 75, 479.e17, 10.1016/j.crad.2020.01.012 Van Houdt, 2017, Needle tract seeding following core biopsies in retroperitoneal sarcoma, Eur. J. Surg. Oncol. J. Eur. Soc. Surg. Oncol. Br. Assoc. Surg. Oncol., 43, 1740 Tissier, 2012, Adrenocortical tumors: improving the practice of the Weiss system through virtual microscopy: a National Program of the French Network INCa-COMETE, Am. J. Surg. Pathol., 36, 1194, 10.1097/PAS.0b013e31825a6308 Weiss, 1989, Pathologic features of prognostic significance in adrenocortical carcinoma, Am. J. Surg. Pathol., 13, 202, 10.1097/00000478-198903000-00004 Bisceglia, 2004, Adrenocortical oncocytic tumors: report of 10 cases and review of the literature, Int. J. Surg. Pathol., 12, 231, 10.1177/106689690401200304 Renaudin, 2018, For Comete-Cancer network, clinicopathological description of 43 oncocytic adrenocortical tumors: importance of Ki-67 in histoprognostic evaluation, Mod. Pathol. Off. J. U. S. Can. Acad. Pathol. Inc., 31, 1708 Duregon, 2017, Validation of the prognostic role of the “Helsinki Score” in 225 cases of adrenocortical carcinoma, Hum. Pathol., 62, 1, 10.1016/j.humpath.2016.09.035 Pennanen, 2015, Helsinki score-a novel model for prediction of metastases in adrenocortical carcinomas, Hum. Pathol., 46, 404, 10.1016/j.humpath.2014.11.015 Libé, 2015, Prognostic factors in stage III-IV adrenocortical carcinomas (ACC): an European Network for the Study of Adrenal Tumor (ENSAT) study, Ann. Oncol. Off. J. Eur. Soc. Med. Oncol., 26, 2119, 10.1093/annonc/mdv329 Fassnacht, 2009, Cancer, 115, 243, 10.1002/cncr.24030 Baudin, 2015, Endocrine tumor board of Gustave Roussy, adrenocortical carcinoma, Endocrinol. Metab. Clin. North Am., 44, 411, 10.1016/j.ecl.2015.03.001 Elhassan, 2021, S-GRAS score for prognostic classification of adrenocortical carcinoma: an international, multicenter ENSAT study, Eur. J. Endocrinol., 186, 25, 10.1530/EJE-21-0510 Beuschlein, 2015, Major prognostic role of Ki67 in localized adrenocortical carcinoma after complete resection, J. Clin. Endocrinol. Metab., 100, 841, 10.1210/jc.2014-3182 Assié, 2007, Prognostic parameters of metastatic adrenocortical carcinoma, J. Clin. Endocrinol. Metab., 92, 148, 10.1210/jc.2006-0706 Berruti, 2014, Prognostic role of overt hypercortisolism in completely operated patients with adrenocortical cancer, Eur. Urol., 65, 832, 10.1016/j.eururo.2013.11.006 Assié, 2019, Value of molecular classification for prognostic assessment of adrenocortical carcinoma, JAMA Oncol., 5, 1440, 10.1001/jamaoncol.2019.1558 Yip, 2022, American association of endocrine surgeons guidelines for adrenalectomy: executive summary, JAMA Surg., 10.1001/jamasurg.2022.3544 Marincola Smith, 2018, Role of additional organ resection in adrenocortical carcinoma: analysis of 167 patients from the U.S. adrenocortical carcinoma database, Ann. Surg. Oncol., 25, 2308, 10.1245/s10434-018-6546-y Gaujoux, 2017, joint working group of ESES and ENSAT, European Society of Endocrine Surgeons (ESES) and European Network for the Study of Adrenal Tumours (ENSAT) recommendations for the surgical management of adrenocortical carcinoma, Br. J. Surg., 104, 358, 10.1002/bjs.10414 Delozier, 2021, Implications of conversion during attempted minimally invasive adrenalectomy for adrenocortical carcinoma, Ann. Surg. Oncol., 28, 492, 10.1245/s10434-020-08824-9 Zheng, 2018, Open adrenalectomy versus laparoscopic adrenalectomy for adrenocortical carcinoma: a retrospective comparative study on short-term oncologic prognosis, OncoTargets Ther, 11, 1625, 10.2147/OTT.S157518 Hue, 2021, Reassessing the impact of tumor size on operative approach in adrenocortical carcinoma, J. Surg. Oncol., 123, 1238, 10.1002/jso.26418 Reibetanz, 2012, German ACC study group, Impact of lymphadenectomy on the oncologic outcome of patients with adrenocortical carcinoma, Ann. Surg., 255, 363, 10.1097/SLA.0b013e3182367ac3 Panjwani, 2017, The impact of nodal dissection on staging in adrenocortical carcinoma, Ann. Surg. Oncol., 24, 3617, 10.1245/s10434-017-6064-3 Gerry, 2016, Lymphadenectomy for adrenocortical carcinoma: is there a therapeutic benefit?, Ann. Surg. Oncol., 23, 708, 10.1245/s10434-016-5536-1 Terzolo, 2021, Results of the ADIUVO study, the first randomized trial on adjuvant mitotane in adrenocortical carcinoma patients, J. Endocr. Soc., 5, A166, 10.1210/jendso/bvab048.336 Kroiss, 2011, Drug interactions with mitotane by induction of CYP3A4 metabolism in the clinical management of adrenocortical carcinoma, Clin. Endocrinol. (Oxf.)., 75, 585, 10.1111/j.1365-2265.2011.04214.x Polat, 2009, Radiotherapy in adrenocortical carcinoma, Cancer, 115, 2816, 10.1002/cncr.24331 Fassnacht, 2006, Efficacy of adjuvant radiotherapy of the tumor bed on local recurrence of adrenocortical carcinoma, J. Clin. Endocrinol. Metab., 91, 4501, 10.1210/jc.2006-1007 Gharzai, 2019, Adjuvant radiation improves recurrence-free survival and overall survival in adrenocortical carcinoma, J. Clin. Endocrinol. Metab., 104, 3743, 10.1210/jc.2019-00029 Nelson, 2018, Adjuvant radiation is associated with improved survival for select patients with non-metastatic adrenocortical carcinoma, Ann. Surg. Oncol., 25, 2060, 10.1245/s10434-018-6510-x Sabolch, 2015, Adjuvant radiation therapy improves local control after surgical resection in patients with localized adrenocortical carcinoma, Int. J. Radiat. Oncol. Biol. Phys., 92, 252, 10.1016/j.ijrobp.2015.01.007 Luo, 2017, The efficacy of radiation therapy in adrenocortical carcinoma: A propensity score analysis of a population-based study, Medicine (Baltimore), 96, e6741, 10.1097/MD.0000000000006741 Habra, 2013, A retrospective cohort analysis of the efficacy of adjuvant radiotherapy after primary surgical resection in patients with adrenocortical carcinoma, J. Clin. Endocrinol. Metab., 98, 192, 10.1210/jc.2012-2367 Ardolino, 2020, Advanced Adrenocortical Carcinoma (ACC): a review with focus on second-line therapies, Horm. Cancer., 11, 155, 10.1007/s12672-020-00385-3 Megerle, 2018, Mitotane monotherapy in patients with advanced adrenocortical carcinoma, J. Clin. Endocrinol. Metab., 103, 1686, 10.1210/jc.2017-02591 Fassnacht, 2012, Combination chemotherapy in advanced adrenocortical carcinoma, N. Engl. J. Med., 366, 2189, 10.1056/NEJMoa1200966 Jouinot, 2018, Pharmacokinetic interaction between mitotane and etoposide in adrenal carcinoma: a pilot study, Endocr. Connect., 7, 1409, 10.1530/EC-18-0428 Sperone, 2010, Gemcitabine plus metronomic 5-fluorouracil or capecitabine as a second-/third-line chemotherapy in advanced adrenocortical carcinoma: a multicenter phase II study, Endocr. Relat. Cancer., 17, 445, 10.1677/ERC-09-0281 Henning, 2017, Gemcitabine-based chemotherapy in adrenocortical carcinoma: a multicenter study of efficacy and predictive factors, J. Clin. Endocrinol. Metab., 102, 4323, 10.1210/jc.2017-01624 Lerario, 2014, The combination of insulin-like growth factor receptor 1 (IGF1R) antibody cixutumumab and mitotane as a first-line therapy for patients with recurrent/metastatic adrenocortical carcinoma: a multi-institutional NCI-sponsored trial, Horm. Cancer., 5, 232, 10.1007/s12672-014-0182-1 Fassnacht, 2015, Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study, Lancet Oncol., 16, 426, 10.1016/S1470-2045(15)70081-1 Kroiss, 2012, Sunitinib in refractory adrenocortical carcinoma: a phase II, single-arm, open-label trial, J. Clin. Endocrinol. Metab., 97, 3495, 10.1210/jc.2012-1419 Kroiss, 2020, Objective response and prolonged disease control of advanced adrenocortical carcinoma with cabozantinib, J. Clin. Endocrinol. Metab., 105, dgz318, 10.1210/clinem/dgz318 Habra, 2019, Phase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinoma, J. Immunother. Cancer., 7, 253, 10.1186/s40425-019-0722-x Raj, 2020, PD-1 blockade in advanced adrenocortical carcinoma, J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol., 38, 71, 10.1200/JCO.19.01586 Carneiro, 2019, Nivolumab in metastatic adrenocortical carcinoma: results of a phase 2 trial, J. Clin. Endocrinol. Metab., 104, 6193, 10.1210/jc.2019-00600 Le Tourneau, 2018, Avelumab in patients with previously treated metastatic adrenocortical carcinoma: phase 1b results from the JAVELIN solid tumor trial, J. Immunother. Cancer., 6, 111, 10.1186/s40425-018-0424-9 Klein, 2021, Combination immunotherapy with ipilimumab and nivolumab in patients with advanced adrenocortical carcinoma: a subgroup analysis of CA209-538, Oncoimmunology, 10, 10.1080/2162402X.2021.1908771 Bedrose, 2020, Combined lenvatinib and pembrolizumab as salvage therapy in advanced adrenal cortical carcinoma, J. Immunother. Cancer., 8, 10.1136/jitc-2020-001009 Papewalis, 2006, Dendritic cells as potential adjuvant for immunotherapy in adrenocortical carcinoma, Clin. Endocrinol. (Oxf.)., 65, 215, 10.1111/j.1365-2265.2006.02576.x Jimenez, 2022, Endocrine and neuroendocrine tumors special issue-checkpoint inhibitors for adrenocortical carcinoma and metastatic pheochromocytoma and paraganglioma: do they work?, Cancers, 14, 467, 10.3390/cancers14030467 Baudin, 2022, EO2401, a novel microbiome-derived therapeutic vaccine for patients with adrenocortical carcinoma (ACC): Preliminary results of the SPENCER study, J. Clin. Oncol., 40, 4596, 10.1200/JCO.2022.40.16_suppl.4596 Hahner, 2012, [131I]iodometomidate for targeted radionuclide therapy of advanced adrenocortical carcinoma, J. Clin. Endocrinol. Metab., 97, 914, 10.1210/jc.2011-2765 Grisanti, 2020, Treatment with 90Y/177Lu-DOTATOC in patients with metastatic adrenocortical carcinoma expressing somatostatin receptors, J. Clin. Endocrinol. Metab., 105, dgz091, 10.1210/clinem/dgz091